ON01210.Na (Ex-RAD®) Mitigates Radiation Damage through Activation of the AKT Pathway

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Kang, Anthony D ^a,c   Cosenza, Stephen C ^a,d   Bonagura, Marie ^a   Manair, Manoj ^b   Reddy, M V Ramana ^a,d   Reddy, E Premkumar ^a,d  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Onconova Therapeutics Inc   (United States)

^c ARMED FORCES RADIOBIOLOGY RESEARCH INSTITUTE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ON 01210NA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RECILISIB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL PROTECTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVATION; FEMALE; FIBROBLAST; HEMATOPOIETIC SYSTEM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; RADIATION EXPOSURE; RADIATION INJURY; RADIATION PROTECTION; UPREGULATION;

ANIMALS; BONE MARROW CELLS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION-PROTECTIVE AGENTS; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; SULFONAMIDES;

EID: 84874731713     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058355     Document Type: Article

References (36)

1. Paris F, Grassme H, Cremesti A, Zager J, Fong Y, et al. (2001) Natural ceramide reverses Fas resistance of acid sphingomyelinase(-/-) hepatocytes. J Biol Chem 276: 8297-8305.
2. Langell J, Jennings R, Clark J, Jr WJ, (2008) Pharmacological agents for the prevention and treatment of toxic radiation exposure in spaceflight. Aviat Space Environ Med 79: 651-660.
3. Waselenko JK, MacVittie TJ, Blakely WF, Pesik N, Wiley AL, et al. (2004) Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med 140: 1037-1051.
4. Dumont F Le Roux A, (2010) Bischoff (2010) Radiation countermesure agents: an update. Expert Opin. Ther. Patents 20(1): 73-101.
5. Reddy EP, Reddy MVR (2004) "(E)-Styryl Sulfone Anticancer Agents". In: USPTO, editor. U.S.: Temple University.
6. Reddy EP, Reddy MVR, Cosenza SC (2002) Method for protecting cells and tissues from ionizing radiation toxicity with alpha, beta unsaturated aryl sulfones. Temple University, Onconova Therapeutics, Inc.
7. Ghosh SP, Perkins MW, Hieber K, Kulkarni S, Kao TC, et al. (2009) Radiation protection by a new chemical entity, Ex-Rad: efficacy and mechanisms. Radiat Res 171: 173-179.
8. Hall EJ, Giaccia AJ (2006) Radiobiology for the radiologist. Philadelphia: Lippincott Williams & Wilkins. ix, 546 p.
9. Denekamp J, (1986) Cell kinetics and radiation biology. Int J Radiat Biol Relat Stud Phys Chem Med 49: 357-380.
10. Dainiak N, (2002) Hematologic consequences of exposure to ionizing radiation. Exp Hematol 30: 513-528.
11. Dainiak N, Waselenko JK, Armitage JO, MacVittie TJ, Farese AM (2003) The hematologist and radiation casualties. Hematology Am Soc Hematol Educ Program: 473-496.
12. Hosseinimehr SJ, (2007) Trends in the development of radioprotective agents. Drug Discov Today 12: 794-805.
13. Porta C, Maiolo A, Tua A, Grignani G, (2000) Amifostine, a reactive oxigen species scavenger with radiation- and chemo-protective properties, inhibits in vitro platelet activation induced by ADP, collagen or PAF. Haematologica 85: 820-825.
14. List AF, Heaton R, Glinsmann-Gibson B, Capizzi RL, (1998) Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors. Leukemia 12: 1596-1602.
15. Ramdas J, Warrier RP, Scher C, Larussa V, (2003) Effects of amifostine on clonogenic mesenchymal progenitors and hematopoietic progenitors exposed to radiation. J Pediatr Hematol Oncol 25: 19-26.
16. Suman S, Datta K, Doiron K, Ren C, Kumar R, et al. (2012) Radioprotective effects of ON01210.Na upon oral administration. J Radiat Res. 53: 368-76.
17. Datta SR, Brunet A, Greenberg ME, (1999) Cellular survival: a play in three Akts. Genes Dev 13: 2905-2927.
18. Franke TF, (2008) PI3K/Akt: getting it right matters. Oncogene 27: 6473-6488.
19. Bonnaud S, Niaudet C, Legoux F, Corre I, Delpon G, et al. (2010) Sphingosine-1-phosphate activates the AKT pathway to protect small intestines from radiation-induced endothelial apoptosis. Cancer Res 70: 9905-9915.
20. Thotala DK, Hallahan DE, Yazlovitskaya EM, (2008) Inhibition of glycogen synthase kinase 3 beta attenuates neurocognitive dysfunction resulting from cranial irradiation. Cancer Res 68: 5859-5868.
21. Eldar-Finkelman H, (2002) Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med 8: 126-132.
22. Gupta AK, Bakanauskas VJ, McKenna WG, Bernhard EJ, Muschel RJ, (2001) Ras regulation of radioresistance in cell culture. Methods Enzymol 333: 284-290.
23. Gupta AK, Cerniglia GJ, Mick R, Ahmed MS, Bakanauskas VJ, et al. (2003) Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys 56: 846-853.
24. Yazlovitskaya EM, Edwards E, Thotala D, Fu A, Osusky KL, et al. (2006) Lithium treatment prevents neurocognitive deficit resulting from cranial.
25. Gumireddy K, Baker SJ, Cosenza SC, John P, Kang AD, et al. (2005) A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci U S A 102: 1992-1997.
26. Reddy MV, Mallireddigari MR, Cosenza SC, Pallela VR, Iqbal NM, et al. (2008) Design, synthesis, and biological evaluation of (E)-styrylbenzylsulfones as novel anticancer agents. J Med Chem 51: 86-100.
27. Stone HB, Moulder JE, Coleman CN, Ang KK, Anscher MS, et al. (2004) Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003. Radiat Res 162: 711-728.
28. Moulder JE, Cohen EP, (2007) Future strategies for mitigation and treatment of chronic radiation-induced normal tissue injury. Semin Radiat Oncol 17: 141-148.
29. Song G, Ouyang G, Bao S, (2005) The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9: 59-71.
30. Trowbridge JJ, Xenocostas A, Moon RT, Bhatia M, (2006) Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation. Nat Med 12: 89-98.
31. Yost C, Torres M, Miller JR, Huang E, Kimelman D, et al. (1996) The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 10: 1443-1454.
32. Jia J, Tong C, Jiang J, (2003) Smoothened transduces Hedgehog signal by physically interacting with Costal2/Fused complex through its C-terminal tail. Genes Dev 17: 2709-2720.
33. Foltz DR, Santiago MC, Berechid BE, Nye JS, (2002) Glycogen synthase kinase-3beta modulates notch signaling and stability. Curr Biol 12: 1006-1011.
34. Juntilla MM, Patil VD, Calamito M, Joshi RP, Birnbaum MJ, et al. (2010) AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species. Blood 115: 4030-4038.
35. Paris F, Fuks Z, Kang A, Capodieci P, Juan G, et al. (2001) Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293: 293-297.
36. Bonnaud S, Niaudet C, Legoux F, Corre I, Delpon G, et al. (2010) Sphingosine-1-phosphate activates the AKT pathway to protect small intestines from radiation-induced endothelial apoptosis. Cancer Res 70: 9905-9915.